Suboptimal disease control and contributing factors in Italian IBD patients: The IBD-PODCAST Study.

Disease control IBD Management strategies Red flags STRIDE II criteria

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
ISSN: 1878-3562
Titre abrégé: Dig Liver Dis
Pays: Netherlands
ID NLM: 100958385

Informations de publication

Date de publication:
18 Sep 2024
Historique:
received: 11 03 2024
revised: 31 07 2024
accepted: 09 08 2024
medline: 20 9 2024
pubmed: 20 9 2024
entrez: 19 9 2024
Statut: aheadofprint

Résumé

Suboptimal disease control (SDC) and its contributing factors in IBD according to STRIDE-II criteria is unclear. IBD-PODCAST was a non-interventional, international, multicenter real-world study to assess this. Data from the Italian IBD cohort (N=220) are presented here. Participants aged ≥19 with confirmed IBD diagnosis of ≥1 year were consecutively enrolled. A retrospective chart review and cross-sectional assessment by physicians and patients within the past 12 months were performed. SDC or optimal disease control was assessed using adapted STRIDE-II criteria. At the index date, 53.4 % of 116 CD patients and 49.0 % of 104 UC patients had SDC, mainly attributed to a Short Inflammatory Bowel Disease Questionnaire score <50, failure to achieve endoscopic remission, and the presence of active extra-intestinal manifestations in both diseases. Disease monitoring with imaging and/or endoscopy during the previous year was conducted in ∼50 % of patients, with endoscopy performed in ∼40 %. Potential therapeutic adjustments were reported for half of the patients. This study highlights SDC in a significant portion of IBD Italian patients. These results emphasize the need for more proactive management strategies in both CD and UC patients.

Sections du résumé

BACKGROUND AND AIM OBJECTIVE
Suboptimal disease control (SDC) and its contributing factors in IBD according to STRIDE-II criteria is unclear. IBD-PODCAST was a non-interventional, international, multicenter real-world study to assess this.
METHODS METHODS
Data from the Italian IBD cohort (N=220) are presented here. Participants aged ≥19 with confirmed IBD diagnosis of ≥1 year were consecutively enrolled. A retrospective chart review and cross-sectional assessment by physicians and patients within the past 12 months were performed. SDC or optimal disease control was assessed using adapted STRIDE-II criteria.
RESULTS RESULTS
At the index date, 53.4 % of 116 CD patients and 49.0 % of 104 UC patients had SDC, mainly attributed to a Short Inflammatory Bowel Disease Questionnaire score <50, failure to achieve endoscopic remission, and the presence of active extra-intestinal manifestations in both diseases. Disease monitoring with imaging and/or endoscopy during the previous year was conducted in ∼50 % of patients, with endoscopy performed in ∼40 %. Potential therapeutic adjustments were reported for half of the patients.
CONCLUSIONS CONCLUSIONS
This study highlights SDC in a significant portion of IBD Italian patients. These results emphasize the need for more proactive management strategies in both CD and UC patients.

Identifiants

pubmed: 39299813
pii: S1590-8658(24)00957-5
doi: 10.1016/j.dld.2024.08.040
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Competing interests

Auteurs

Emma Calabrese (E)

Gastroenterology Unit, Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy. Electronic address: emma.calabrese@uniroma2.it.

Sara Onali (S)

Gastroenterogy Unit, Dep. of Medical Scienze and Public Health, University of Cagliari, Italy.

Angela Variola (A)

IBD Unit, IRCCS Sacro Cuore Don Calabria, Negrar di Valpolicella, Verona, Italy.

Davide Giuseppe Ribaldone (DG)

Department of Medical Sciences, University of Turin, Italy.

Edoardo Vincenzo Savarino (EV)

Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; Gastroenterology Unit, Azienda Ospedale Università di Padova, Padua, Italy.

Anna Viola (A)

IBD-Unit, Department of Clinical and Experimental Medicine, University of Messina, Messina, Ital.

Simone Saibeni (S)

IBD Center, Gastroenterology Unit, Rho Hospital, ASST Rhodense, Milan, Italy.

Francesco Simone Conforti (FS)

Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Anna Testa (A)

Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.

Giovanni Latella (G)

Gastroenterology Unit, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Ambrogio Orlando (A)

IBD Unit, `Villa Sofia-Cervello' Hospital, Palermo, Italy.

Mariabeatrice Principi (M)

Gastroenterology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari, Italy.

Antonino Carlo Privitera (AC)

IBD Unit, "Cannizzaro" Hospital, Catania, Italy.

Maria Guerra (M)

Division of Gastroenterology and Endoscopy, Fondazione IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Foggia, Italy.

Linda Ceccarelli (L)

Gastroenterology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.

Giammarco Mocci (G)

Division of Gastroenterology, ARNAS G."Brotzu" Hospital, Cagliari, Italy.

Davide Boy (D)

Medical Department, AbbVie Srl, Campoverde, Latina, Roma, Italy.

Maria Adelaide Piccarozzi (MA)

Medical Department, AbbVie Srl, Campoverde, Latina, Roma, Italy.

Giuliana Gualberti (G)

Medical Department, AbbVie Srl, Campoverde, Latina, Roma, Italy.

Francesca Marando (F)

Medical Department, AbbVie Srl, Campoverde, Latina, Roma, Italy.

Lorenzo Gemignani (L)

Medical Department, AbbVie Srl, Campoverde, Latina, Roma, Italy.

Ferdinando D'Amico (F)

Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele Milano, Milan, Italy.

Classifications MeSH